Citations

Clear

3030 citation(s) found for "Susan, M".

Evaluation of Soy Phytoestrogens for the Treatment of Hot Flashes in Breast Cancer Survivors: A North Central Cancer Treatment Group Trial
Quella, Susan K., Loprinzi, Charles L. , Barton, Debra L. , Knost, James A., Sloan, Jeff A. , LaVasseur, Beth, Swan, Debra, Krupp, Kenneth R., Novotny, Paul J. , Miller, Kathy D.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 18 | Issue: 5 | Pages: 1068-1068

10.1200/jco.2000.18.5.1068 | PMID 10694559 Get It

PURPOSE: Hot flashes represent a significant clinical problem for some breast cancer survivors. Safe, effective treatment is needed for this prominent clinical problem. Although it has been shown that estrogen or progesterone replacement therapy can alleviate this problem, there are continued safety concerns regarding the use of hormonal therapies in these women. Based on anecdotal information, we hypothesized that soy-derived phytoestrogens, weak estrogen-like substances in the soybean that demonstrate estrogen agonist and/or antagonist effects when they bind to estrogen receptors, could alleviate hot flashes. This current trial was designed to investigate this hypothesis.PATIENTS AND METHODS: This double-blind clinical trial involved breast cancer survivors with substantial hot flashes. After randomization, patients underwent a 1-week baseline period with no therapy. This was followed by 4 weeks of either soy tablets or placebo. The patients then crossed over to the opposite arm in a double-blind manner for the last 4 weeks. Patients completed a daily questionnaire documenting hot flash frequency, intensity, and perceived side effects.RESULTS: Of the 177 women who were randomized and started the study substance, 155 (88%) provided useable data over the first 5 weeks; 149 provided usable data over the entire 9 weeks. There was no suggestion that the soy product was more effective in reducing hot flashes than the placebo. At study completion, patients preferred the soy product 33% of the time, the placebo 37% of the time, and neither substance 31% of the time. No toxicity was observed.CONCLUSION: The soy product did not alleviate hot flashes in breast cancer survivors.
Sentinel Lymph Node Biopsy With Metastasis: Can Axillary Dissection Be Avoided in Some Patients With Breast Cancer?
Reynolds, Carol, Mick, Rosemarie , Donohue, John H., Grant, Clive S., Farley, David R. , Callans, Linda S., Orel, Susan G., Keeney, Gary L., Lawton, Thomas J. , Czerniecki, Brian J.

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 17 | Issue: 6 | Pages: 1720-1720

10.1200/jco.1999.17.6.1720 | PMID 10561208 Get It

PURPOSE: Recent studies have suggested that the sentinel lymph node (SLN) biopsy is an accurate alternative staging procedure for women with breast cancer. The goal of this study was to identify a subset of breast cancer patients in whom metastatic disease was confined only to the SLN. MATERIALS AND METHODS: From two institutions, we recruited 222 women with breast cancer for SLN biopsy. A SLN biopsy was performed in each patient, followed by an axillary dissection in 182 patients. Histologic and immunohistochemical cytokeratin stains were used on all SLNs. RESULTS: The SLN was identified in 220 (97.8%) of the 225 biopsies. Evidence of metastatic breast cancer in the SLN was found in 60 (27.0%) of the 222 patients. Of these patients, 32 (53.3%) had evidence of tumor in the SLN only. By multivariate analysis, two factors were found to be significantly associated with a higher likelihood of tumor involvement in the non-SLNs: primary tumor size larger than 2.0 cm (P = .0004) and macrometastasis (> 2.0 mm) in the SLN (P = .002). Additional analysis revealed that none (0%; 95% confidence interval, 0% to 18.5%) of the 18 patients with primary tumors ≤ 2.0 cm and micrometastasis to the SLN had remaining axillary lymph node involvement. CONCLUSION: The primary tumor size and metastasis size in the SLN are independent factors in predicting the incidence of tumor in the non-SLNs. Therefore, the SLN biopsy alone may be adequate for staging and/or therapy decision making in patients with primary breast tumors ≤ 2.0 cm and micrometastasis in the SLN.
Effectiveness and safety of second-line (2L) irinotecan- and oxaliplatin-based regimens after first-line (1L) bevacizumab (BV)-containing treatment (tx) for metastatic colorectal cancer (mCRC): Results from the ARIES observational cohort study.
Bendell, Johanna C. , Kozloff, M., Cohn, Allen Lee, Mun, Yong, Fish, Susan, Flick, E. Dawn, Dalal, Darshan, Hurwitz, Herbert I. , Bekaii‐Saab, Tanios , Grothey, Axel

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 30 | Issue: 4_suppl | Pages: 535-535

10.1200/jco.2012.30.4_suppl.535 Get It

535 Background: Prior ARIES analyses showed that BV-treated mCRC patients (pts) receiving chemotherapy (CT)/biologics + BV within 2 months (mo) after 1st progressive disease (PD) had longer post-progression survival (PPS) than pts receiving only CT/biologics. The present analysis evaluated whether this effect of BV was consistent when used with common 2L CT regimens— irinotecan- (iri-) and oxaliplatin- (ox-) based—in mCRC pts exposed to 1L BV in ARIES. Methods: ARIES enrolled mCRC pts receiving 1L CT + BV. No tx regimens or assessments were protocol specified. This analysis evaluated 1L BV-treated mCRC pts who had PD, survived ≥2 mo after PD, and received 2L iri- or ox-based tx. PPS was estimated by Kaplan-Meier methods. Cox regression was used to estimate hazard ratios (HRs), while adjusting for covariates (eg, 1L time to progression). Results: Of 1550 1L pts in ARIES, 1074 had 1st PD and survived ≥2 mo after PD. Of these 1074, 390 and 114 received 2L iri- and ox-based tx, respectively, ± BV ( table ). Baseline characteristics were generally similar between groups. The incidence of targeted adverse events (TAEs) was as expected and similar between the BV and No BV groups over time. In pts receiving 2L iri- or ox-based CT tx, PPS in BV-treated pts was longer compared to those not on BV. Analyses may be limited by small pt numbers in some groups. Conclusions: Consistent with prior ARIES analyses, the continued use of BV after 1st PD was associated with prolonged PPS regardless of the 2L CT backbone used. [Table: see text]
Quality assurance review center: Role in multi-institutional breast cancer trials.
Moni, Janaki, Le‐Petross, Huong T. , Boughey, JC , Laurie, F., Hanusik, Richard, Howley, Susan, Logan, D, Bishop‐Jodoin, Maryann , Simmons, R.M., Ellis, MJ, Hunt, Katie N. , Cicchetti, M. Giulia, Sioshansi, Shirin, Quinlan, Robert, Whalen, G, FitzGerald, Thomas J.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 29 | Issue: 27_suppl | Pages: 205-205

10.1200/jco.2011.29.27_suppl.205 Get It

205 Background: Central review is an important trial management and validation tool. Multisite trials require data systems to accommodate diverse image acquisition and review. Breast cancer is challenging as its imaging objects are not always easily shared across departments. Quality Assurance Review Center (QARC) has a diverse portfolio of facile data acquisition and powerful informatics support that meets these needs. We report on the role of QARC in three of the current breast cancer trials from the American College of Surgeons Oncology Group. Methods: QARC data management system includes secure network infrastructure and a validated relational operating database (MAX). QARC has data acquisition/imaging re-distribution expertise for real time response reviews, response measuring tools and corresponding data archive for secondary reviews. MAX includes query ability; records link to digital information. QARC underwent systematic information systems validation process for 21 CFR Part 11. DICOM/non-DICOM files are stored in the QARC PACS. On-site/remote reviewers use MAX to retrieve, view, annotate and save images. Data extracted is securely sent to partner statistical centers. Results: In Z1031, a neoadjuvant endocrine therapy trial, all of the mammographic exams are archived at QARC. For Z1071, a sentinel lymph node trial, pre- and post-treatment ultrasound (US) images of 321 patients were remotely reviewed. For Z1072, the cryoablation US, pre and post-cryoablation MRI for 40 of 47 cases were remotely archived, retrieved and transferred to investigator workstation for post-processing and review. The other 7 patients did not have evaluable imaging studies. In all three trials, the costs of shipping hardcopies of exams and travel to QARC for central review functions were eliminated. Conclusions: QARC data management systems provide diverse informatics supports for multi-institutional trials, ranging from archives of images, provide remote access and download of data, and central review. The vibrant informatics supports meet the growing needs of clinical trials. Future directions include radiation field review for breast cancer trials and the incorporation of pathology microarray analysis as DICOM objects.
Anti-tumor activity of low-dose single agent CCI-779 for relapsed mantle celllLymphoma: A phase II trial in the North Central Cancer Treatment Group
Ansell, Stephen M. , Geyer, Susan M. , Kurtin, Paul J. , Rowland, Kendrith M. , Flynn, Patrick J. , Morton, Roscoe F., Dakhil, Shaker R. , Gross, Howard M., Witzig, Thomas E. , Maurer, Matthew J. , Kaufmann, Scott H.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 6504-6504

10.1200/jco.2005.23.16_suppl.6504 Get It

Clinicians' Views on Management and Terminology for Papillary Thyroid Microcarcinoma: A Qualitative Study
Nickel, Brooke , Brito, Juan P. , Barratt, Alexandra , Jordan, Susan J. , Moynihan, Ray , McCaffery, Kirsten , Brito, Juan P

Mayo Clinic

Thyroid | February 22, 2017 | Volume: 27 | Issue: 5 | Pages: 661-671

10.1089/thy.2016.0483 | PMID 28322617 Get It

Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial
Shoaf, Susan E. , Chapman, Arlene B., Torres, Vicente E. , Ouyang, John , Czerwiec, Frank S., Torres, Vicente E

Mayo Clinic

The Journal of Clinical Pharmacology | February 20, 2017 | Volume: 57 | Issue: 7 | Pages: 906-917

10.1002/jcph.880 | PMID 28218410 Get It

A risk prediction score for acute kidney injury in the intensive care unit
Malhotra, Rakesh , Macedo, Etienne , Kim, Jihoon , Bouchard, Josée , Wynn, Susan, Li, Guangxi , Ohno‐Machado, Lucila , Mehta, Ravindra L. , Kashani, Kianoush , Mehta, Ravindra L , Macedo, Etienne , Li, Guangxi

Mayo Clinic

Nephrology Dialysis Transplantation | February 15, 2017 | Volume: 32 | Issue: 5 | Pages: 814-822

10.1093/ndt/gfx026 | PMID 28402551 Get It

Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals
Tosun, Duygu , Landau, Susan , Aisen, Paul , Petersen, Ronald C. , Mintun, Mark A., Jagust, William, Weiner, Michael W. , Initiative, for the Alzheimer’s Disease Neuroimaging, Initiative, for the Alzheimer’s Disease Neuroimaging, Tosun, Duygu

Mayo Clinic

Brain | February 15, 2017 | Volume: 140 | Issue: 5 | Pages: 1499-1512

10.1093/brain/awx046 | PMID 28334939 Get It

Globicatella sanguinis Osteomyelitis and Bacteremia: Review of an Emerging Human Pathogen with an Expanding Spectrum of Disease
Buckwalter, Seanne P., Henry, Michael , Wu, Fann , Maloney, Katherine F., Abraham, Bisrat , Hartman, Barry J., Brause, Barry D. , Whittier, Susan , Walsh, Thomas J. , Miller, Andy , Schuetz, Audrey N.

Mayo Clinic

Open Forum Infectious Diseases | February 13, 2017 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/ofid/ofw277 | PMID 28480269 Get It

AbstractBackgroundGlobicatella sanguinis is an uncommon pathogen that may be misdiagnosed as viridans group streptococci. We review the literature of Globicatella and report 2 clinical cases in which catalase-negative Gram-positive cocci resembling viridans group streptococci with elevated minimum inhibitory concentrations (MICs) to ceftriaxone were inconsistently identified phenotypically, with further molecular characterization and ultimate identification of G sanguinis.MethodsTwo clinical strains (from 2 obese women; 1 with a prosthetic hip infection and the other with bacteremia) were analyzed with standard identification methods, followed by matrix-assisted laser desorption ionization time-of-flight mass spectrometry, 16S recombinant ribonucleic acid (rRNA), and sodA polymerase chain reaction (PCR). The existing medical literature on Globicatella also was reviewed.ResultsStandard phenotypic methods failed to consistently identify the isolates. 16S PCR yielded sequences that confirmed Globicatella species. sodA sequencing provided species-level identification of G sanguinis. The review of literature reveals G sanguinis as an increasingly reported cause of infections of the urine, meninges, and blood. To our knowledge, this is the first reported case of an orthopedic infection caused by Globicatella sanguinis. A review of the 37 known cases of G sanguinis infection revealed that 83% of patients are female, and 89% are at the extremes of age (<5 or >65 years).ConclusionsGlobicatella sanguinis, an uncommon pathogen with elevated minimum inhibitory concentrations to third-generation cephalosporins, is difficult to identify by phenotypic methods and typically causes infections in females at the extremes of age. It may colonize skin or mucosal surfaces. Advanced molecular techniques utilizing 16S rRNA with sodA PCR accurately identify G sanguinis.